CORONAVIRUS INFO PROVIDED BY DR. JIM HARRIS – 8/26/2022

HAVE A NICE WEEKEND. LOCAL COUNTS CONTINUE TO DECREASE. THE STATE HAS SLOWED DOWN ITS STAT GATHERING.

UP TO DATE CAC VACCINE INFORMATION

LONG COVID STUDIES FROM SOUTHWESTERN MEDICAL SCHOOL

FROM HOPKINS SUGGESTIONS:

1. INCUBATION PERIOD According to a study published August 22 in JAMA Network Open, the incubation period of COVID-19 has decreased gradually as SARS-CoV-2 has continuously evolved and mutated, producing variants with different enhanced transmission and virulence. The incubation period is the interval between exposure and development of symptoms and is an important epidemiologic indicator for understanding transmission. Based on the authors’ meta-analysis, the initial “wild type” strain first detected in Wuhan, China, in 2019 had an incubation period of approximately 5.2 days. Later in 2020, the Alpha variant that quickly became dominant in the UK had an incubation period of about 5 days. The Beta variant was identified shortly after and showed a shortened incubation period of 4.5 days, followed by the Delta variant with 4.41 days. The incubation period for Omicron infection is currently 3.42 days. While a decrease in incubation period often is associated with more severe disease, the decrease with COVID-19 means it makes it much more difficult to control transmission, because the faster someone becomes contagious, the faster an outbreak spreads. Knowledge of this key epidemiological parameter is helpful not only in reducing local transmission but also in understanding presymptomatic transmission.

2. PAXLOVID REBOUND The US FDA has requested that Pfizer conduct a study examining an extended course of its antiviral Paxlovid among individuals who experience a rebound of COVID-19 after taking an initial 5-day course. The FDA wants to know if a second 5-day course of the antiviral would help prevent disease rebound, and has requested that Pfizer produce initial results of such a trial by September 30, 2023. While Pfizer claims that disease rebound following Paxlovid treatment remains rare, several high-profile cases have prompted the FDA’s request for further study into the phenomenon. 

3. US BOOSTER CAMPAIGN Following recent news regarding the authorization of variant-adapted SARS-CoV-2 vaccine boosters in the UK and applications for emergency use authorization (EUA) of BA.4/BA.5 boosters in the US (both Pfizer-BioNTech and Moderna), US government officials have signaled that variant-adapted booster doses could be available for individuals aged 12 years and older by early September. The bivalent vaccines will target both the original strain of SARS-CoV-2 and both the BA.4 and BA.5 sublineages (since they share common mutations to the spike protein).

While human clinical trials have not yet been conducted, the agency’s Director of the Center for Biologics Evaluation and Research (CBER), Dr. Peter Marks, indicated that he is “extremely confident” that the trials will demonstrate the candidate boosters to be safe and efficacious. In contrast to regulatory review of previous SARS-CoV-2 vaccine candidates, the FDA is not waiting on the completion of human clinical trials. Rather, the agency will base their assessment primarily on data from animal models and previous clinical trial data on BA.1-adapted bivalent candidate vaccines, a process similar to how the FDA reviews seasonal influenza vaccines. Clinical trials for the candidate boosters in humans are expected to begin this month. Reportedly, the FDA does not intend to convene its Vaccines and Related Biological Products Advisory Committee (VRBPAC) to discuss the candidate boosters; however, the CDC’s Advisory Committee on Immunization Practices (ACIP) has tentatively scheduled a meeting for September 1-2 in anticipation of a FDA decision. 

Some experts have expressed doubt regarding the need for a BA.4/BA.5-specific booster, as it may provide little additional protection for the millions of people who have already been exposed to one of those variants. Similarly, antibodies generated to protect against BA.4/BA.5 may not provide sufficient protection against other emerging variants, such as BA.2.75. While some experts are concerned that the abbreviated regulatory review risks increasing vaccine hesitancy and mistrust among the public, others argue that it is critical to make variant-adapted boosters available quickly, to provide protection before the virus evolves further and new variants emerge.

(J. Harris: I plan to follow this vaccine closely.)

4. Moderna sues Pfizer and BioNTech over coronavirus vaccine patent (Washington Post) Moderna sued Pfizer and its German partner BioNTech on Friday, alleging the rival firms improperly used its foundational technology in developing their coronavirus vaccine. The suit sets up a legal battle between the most prominent companies that helped curb the coronavirus pandemic in the United States by developing highly effective shots in record time. “We believe that Pfizer and BioNTech unlawfully copied Moderna’s inventions, and they have continued to use them without permission,” Moderna Chief Legal Officer Shannon Thyme Klinger said in a company news release. The company said it filed suits in U.S. District Court in Massachusetts and in Germany, where BioNTech is headquartered.

BECKERS reports:

1. 3 medications fail as possible COVID-19 treatments

2. Student debt relief’s effect on physicians, nurses: 5 notes

(J. Harris: Would that we could give them some relief while also requiring that they serve where they are most needed for a prescribed period of time.)

FROM YOUR LOCAL EPIDEMIOLOGIST:

Fall boosters: An update

(J. Harris: Good read.)

FROM THE NEJM:

Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge

”…Among patients 65 years of age or older, the rates of hospitalization and death due to Covid-19 were significantly lower among those who received nirmatrelvir than among those who did not. No evidence of benefit was found in younger adults.”

FROM THE ATLANTIC:

1. America’s Fall Booster Plan Has a Fatal Paradox

”…we might finally be getting inoculations that are well matched to the season’s circulating strains…..America is still stuck on … two very shaky assumptions, perhaps both doomed to fail: that the shots can and should sustainably block infection, and that “people will actually go and get the vaccine,..In terms of both content and timing, the fall shot will be one of the most important COVID vaccines offered to Americans since the initial doses… COVID vaccines, like most others, are best at staving off severe disease and death; against BA.5 and its kin, especially, that protection is likely to be durable and strong. But those same shields will be far more flimsy and ephemeral against milder cases or transmission, and can only modestly cut down the risk of long COVID. And when partnered with a compromised or elderly immune system, the shots have that much less immunological oomph…The U.S. needs people to take this vaccine because it has nothing else. But its residents are unlikely to take it, because they’re not doing anything else…Shots, to be abundantly clear, are essential to building up a properly defensive anti-COVID wall. But they are not by themselves sufficient to keep invaders out. Like bricks stacked without a foundation or mortar, they will slip and slide and crumble. Nor is a wall with too few bricks likely to succeed: If the goal is to preemptively quell a winter case surge, “a booster that will have maybe 30 to 40 percent uptake is not something we can expect to have a huge population-level impact,..”

(J. Harris: My personal plan is to take one of the modified vaccines even though they have not been well studied on humans. The basic vaccine has been studied and it works and is as safe as most any other vaccine. I don’t know if I will “Mix and Match” and take Moderna after have had 4 jabs of Pfizer with satisfactory results.)

AND LASTLY:

NORWEGIANS ON VACATION

***********************************

GIVE US YOUR FEEDBACK.  CLICK ON “COMMENT” TO TELL US WHAT YOU THINK or use one of the alternative methods for providing feedback.

Click here to submit feedback.  Let us know what you think.

click here to CLOSE THIS PAGE

—————————————————————–

Click here to go to the iExposed.us youtube channel

Click here to go to the iExposed.us website

—————————————————————–

iExposed Us 

P.O. Box 721

Scottsville Texas

75688

CORONAVIRUS INFO PROVIDED BY DR. JIM HARRIS – 8/25/2022

(J. Harris: Actually, state cases are up after the weekend.)

COVID and Smell Loss: What Doctors Want You to Know

(J. Harris: This article smells good to me. )

YOUR LOCAL EPIDEMIOLOGIST:

State of Affairs: COVID-19, MPX, and …Polio

” …What’s next? One Omicron subvariant, called BA.4.6, is taking hold in the U.S. It doesn’t have a mutation on the spike protein, but another mutation is giving it a slight advantage, causing a very slow take over. We don’t think this will cause a wave, but BA.4.6 may become dominant…

(J. Harris: She has nice, brief summaries which are understandable and seem accurate to me. )

FROM HOPKINS 

1. Omicron-specific Covid booster shots are just weeks away. Here’s who will—and won’t—be eligible (CNBC) Newly updated Covid booster shots designed to target omicron’s BA.5 subvariant should be available within in the next three weeks. That begs an important question: Who’s going to be eligible to get them? The short answer: anyone ages 12 and up who has completed a primary vaccination series, a Centers for Disease Control and Prevention spokesperson tells CNBC Make It. It’s unlikely to matter whether you’ve received any other booster doses or not before, the spokesperson says — but if you’re unvaccinated, you won’t eligible for the updated formula until you complete a primary series with the existing Covid vaccines. 

2. SIGN UP FOR HOPKINS SECURITY NEWSLETTERS

FROM DMN:

How a $100 box is changing the way people protect themselves against coronavirus

(J. Harris: Good PTA project? )

FROM THEN NYT:

SEWAGE PROVIDES A SOLUTION!

***********************************

GIVE US YOUR FEEDBACK.  CLICK ON “COMMENT” TO TELL US WHAT YOU THINK or use one of the alternative methods for providing feedback.

Click here to submit feedback.  Let us know what you think.

click here to CLOSE THIS PAGE

—————————————————————–

Click here to go to the iExposed.us youtube channel

Click here to go to the iExposed.us website

—————————————————————–

iExposed Us 

P.O. Box 721

Scottsville Texas

75688

CORONAVIRUS INFO PROVIDED BY DR. JIM HARRIS – 8/20/2022

This chapter for the Covid saga is fading locally. Harrison County is back in a “Low Danger” Zone. 

Have a nice weekend, but don’t monkey around. 

FROM EPIDEMIOLOGIST:

Why older people are at higher risk for severe COVID-19

(J. Harris: A brief, concise review of immunology that even I can almost understand. Incidentally, I think I’ll keep my nasal iodine solution handy. Anyone can sign up for this informative series.)

HOPKINS’ COVID WEBB SITE (CLICK)

J. Harris: Anyone can sign up for Hopkins viral sites. Free! They are quick to read and very thorough and the most complete and extensive source of information. They send out news several times per week. We haven’t talked about Hopkins’ services to humanity in the last couple of years. 

FROM HOPKINS SUGGESTIONS:

1. In an Effort to Address its Missteps During Covid, CDC Plans an ‘Ambitious’ Agency Overhaul (STAT News) The Centers for Disease Control and Prevention, an agency that has had its reputation battered by a series of missteps in the Covid-19 pandemic, and a slow response to the monkeypox outbreak, will undergo an “ambitious” overhaul, Director Rochelle Walensky announced Wednesday. In an email to staff, Walensky said the renewal effort will focus on making the agency more nimble and responsive to needs that arise in health emergencies. The priority will be to gather data that can be used to rapidly dispense public health guidance, rather than craft scientific pape

FROM BECKERS:

1. Pfizer’s antiviral drug could result in ‘Paxlovid mouth’

2. Century-old tuberculosis vaccine may protect against COVID-19, study finds

”A tuberculosis vaccine that’s 100 years old and costs less than a dollar per dose could have a shot at preventing COVID-19 infections, according to researchers from Boston’s Massachusetts General Hospital…

In a 15-monthslong trial conducted before COVID-19 vaccines were available, the researchers administered three jabs of the Bacillus Calmette-Guerin vaccine, which was first introduced in 1921, to 144 patients with Type 1 diabetes. The vaccine garnered 92 percent efficacy, according to an Aug. 16 press release….

The results, which are published in the Cell Reports Medicine journal, also showed high efficacy in combating other infectious diseases. The researchers hope to start a larger trial to further test the tuberculosis vaccine’s efficacy among patients with Type 1 diabetes, a group that has a high risk for severe illness from COVID-19.” 

FROM TIME MAGAZINE:

Your Kid’s School Needs Better Ventilation to Help Keep COVID-19 in Check

”…some parents and experts are trying to improve ventilation in schools, since better air quality in buildings can reduce COVID-19’s spread and even improve other health outcomes. But, despite readily available resources—including millions of dollars in funding from the federal government—many schools have not invested in upgrading their air quality…. experts recommend that classroom ventilation meets the threshold of six air changes per hour, meaning new, clean air is circulating through the room every ten minutes. …School leaders need to learn more about air quality issues in order to understand how important they are, experts say. Even if an administrator recognizes the value of better ventilation, they likely need to hire an HVAC expert to examine existing building systems, then vet that expert’s recommendations and evaluate potential upgrades—all of which may be “far beyond their area of expertise..”

TO ANSWER A QUESTION MANY ARE ASKING:

Do You Need a Polio Booster Shot?

AND LAST BUT NOT LEASED:

***********************************

GIVE US YOUR FEEDBACK.  CLICK ON “COMMENT” TO TELL US WHAT YOU THINK or use one of the alternative methods for providing feedback.

Click here to submit feedback.  Let us know what you think.

click here to CLOSE THIS PAGE

—————————————————————–

Click here to go to the iExposed.us youtube channel

Click here to go to the iExposed.us website

—————————————————————–

iExposed Us 

P.O. Box 721

Scottsville Texas

75688

CORONAVIRUS INFO PROVIDED BY DR. JIM HARRIS – 8/16/2022

HELLO, AREA ICU CASES HAVE INCREASED. HARRISON COUNTY IN “MODERATE” DANGER ZONE. MASKS IN CROWDS RECOMMENDED.

A reaction to the CDC guidance [READ HOW AN EXPERT FAMILY PERSON PLANS TO HANDLE COVID NOW]

(J. Harris: In my medical opinion, this young Ph.D epidemiologist is wise beyond her years. She writes beautifully while clearly exploring and explaining pertinent and practical medical and public health issues. My highest compliment is “ELEGANT,” and she is.)

FROM HOPKINS SELECTIONS:

1. COVID Rebound is Surprisingly Common — Even without Paxlovid (Nature) After the game-changing COVID-19 antiviral Paxlovid began to be used in late 2021, researchers noticed a perplexing trend. In some people taking the drug, symptoms and detectable virus vanish, only to mysteriously return days later. After months of grasping at straws, scientists are beginning to make some headway in understanding ‘Paxlovid rebound’. Two recent studies suggest that it is surprisingly common for SARS-CoV-2 to return in untreated cases of COVID-19, while hinting that the virus’s comeback is fiercer and more common in people who take Paxlovid.

2. Covid Vaccine Designed to Target Two Variants Approved for Use in UK (The Guardian) A vaccine designed to target two different forms of Covid has been approved by the UK regulator for use as booster jabs in people over the age of 18. Manufactured by the US firm Moderna, the vaccine targets not only the original coronavirus – as is the case for vaccines currently in use – but is designed specifically to target the Omicron variant BA.1, which fuelled a wave of Covid in the UK last winter. The UK is the first country to approve the bivalent vaccine, known as “Spikevax bivalent Original/Omicron”. It is now up to the UK’s Joint Committee on Vaccination and Immunisation (JCVI) to decide whether it will, as expected, be used in the planned autumn booster programme, expected to begin in September.

FROM BECKERS:

1. Longer Paxlovid course needed to prevent rebounds, experts say

***********************************

GIVE US YOUR FEEDBACK.  CLICK ON “COMMENT” TO TELL US WHAT YOU THINK or use one of the alternative methods for providing feedback.

Click here to submit feedback.  Let us know what you think.

click here to CLOSE THIS PAGE

—————————————————————–

Click here to go to the iExposed.us youtube channel

Click here to go to the iExposed.us website

—————————————————————–

iExposed Us 

P.O. Box 721

Scottsville Texas

75688

More Black Former N.F.L. Players Eligible for Concussion Payouts

Tests for dementia were rescored under the N.F.L.’s concussion settlement to avoid race-based criteria.

*****************************

Dozens of Black retired N.F.L. players will now be eligible for payouts worth hundreds of thousands of dollars from the league’s billion-dollar concussion settlement, reversing previous decisions made because of cognitive tests that used race-based measures to determine whether the players had dementia.

The decision, included in a status report filed by the settlement administrator that was entered into the court docket Thursday, came two years after two former players sued the league to end the use of race as a criterion in evaluating the players’ claims, a process known as “race-norming.”

The settlement administrator found that 646 players who had been tested for dementia but did not qualify for cash payouts could have their tests automatically rescored without using race as a criterion.

Of those, 61 were found to have moderate or severe dementia and may receive payouts worth $500,000 or more. The payouts vary based on a player’s age and the number of years he was in the league.

Another 246 former players were found to have mild dementia and will receive additional testing to monitor their conditions. Thousands of other players have qualified for examinations that will not use race as a factor; these players could qualify for payouts in the coming months and years.

The results were the latest chapter in the landmark concussion settlement that has resulted in about $1 billion in claims being paid to players with a range of cognitive and neurological diseases including dementia. For years, former players and their families have accused the league of making it difficult, if not impossible, to receive payouts from the settlement, and they have claimed that the plaintiffs attorney who represents every player in the class-action settlement was not doing enough to fight for them.

Click here to read the complete story 

***********************************

GIVE US YOUR FEEDBACK.  CLICK ON “COMMENT” TO TELL US WHAT YOU THINK or use one of the alternative methods for providing feedback.

Click here to submit feedback.  Let us know what you think.

click here to CLOSE THIS PAGE

—————————————————————–

Click here to go to the iExposed.us youtube channel

Click here to go to the iExposed.us website

—————————————————————–

EastTexasExposed.com

P.O. Box 721

Scottsville Texas

75688

CORONAVIRUS INFO PROVIDED BY DR. JIM HARRIS – 8/12/2022

FROM THE EPIDEMIOLOGIST EXCELLENT ARTICLE FOR EDUCATORS AND PARENTS

A plan for the upcoming school year

(J. Harris: READABLE)

FROM BECKERS: 

 CDC UPDATES CURRENT: AUGUST 11, 2022:

”...While the CDC did away with quarantine recommendations, the new guidance says people exposed to COVID-19 should wear a high-quality mask for 10 days and get tested on day five…he new COVID-19 recommendations focus on mitigating the risk of severe disease, rather than infection itself…We’re in a stronger place today as a nation, with more tools — like vaccination, boosters and treatments — to protect ourselves and our communities, from severe illness from COVID-19…This guidance acknowledges that the pandemic is not over but also helps us move to a point where COVID-19 no longer severely disrupts our daily lives.”

FIVE CDC UPDATES

1. The guidance underscores the importance of staying up to date with vaccination, “especially as new vaccines become available.” Omicron-targeted vaccines are expected to be available in the fall.2. The six-foot standard for social distancing is no longer an explicit recommendation. The guidelines place less emphasis overall on physicial distancing as a key measure to avoid exposure, instead describing it as “just one component of how to protect yourself and others.” The updated recommendations place more onus on individuals to assess the risks and take more precautions in particular settings, such as crowded indoor spaces.

3.  The CDC no longer recommends routine screening of people without symptoms in most community settings, including schools4. Isolation guidance for people with COVID-19 remains the same: Isolate for at least five days at home and wear a high quality-mask when around others. Isolation may be ended after five days if a person is fever-free for 24 hours without medication and symptoms are improving, though a mask should be worn through day 10. Immunocompromised people and those who had more severe illness should isolate through day 10. 

5. The FDA on Aug. 9 released a safety alert advising people to perform repeat testing to avoid false negative results when using at-home rapid antigen tests. If a symptomatic person tests negative, they should test again 48 hours later. People without symptoms who may have been exposed should take up to three tests after receiving their first negative result, each separated by a 48-hour period….Be aware that at-home COVID-19 antigen tests are less accurate than molecular tests,” the FDA said. “COVID-19 antigen tests may not detect the SARS-CoV-2 virus early in an infection, meaning testing soon after you were exposed to someone with COVID-19 could lead to a false-negative result, especially if you don’t have symptoms. This is the reason why repeat testing is important.”

HOPKINS SUGGESTS:

1 Omicron Subvariants Gain More Ground, Including BA.4.6 in the Midwest (CIDRAP) Though the 7-day average for new daily COVID-19 cases is slowly declining, the more transmissible and immune-evasive Omicron subvariants became even more dominant last week, with an offshoot called BA.4.6 gaining traction in some Midwestern states. Health officials brace for a possible spike in activity after school starts and people begin gathering more indoors in the fall. In its weekly variant proportion updates, the U.S. CDC said the proportion of BA.5 viruses in sequenced samples last week rose from 84.5% to 87.1%, while BA.4 declined slightly, from 8.2% to 6.6%. However, the proportion of BA.4.6 viruses rose from 4.2% last week to 4.8% this week. The subvariant has also been reported in other US regions, especially in the east.

2. Community transmission in the US is primarily driven by the Omicron BA.5 sublineage. BA.5 is now projected to account for 87.1% of sequenced specimens. The BA.4 sublineage accounts for about 6.6% of cases, while the BA.4.6 sublineage accounts for 4.8% of cases. Together, BA.2.12.1 and BA.2 now account for only about 2.9% of cases. According to the estimate, Omicron variants represent all new cases in the US.

3. EDUCATORS MIGHT NOTE:

INDOOR AIR WORKSHOP The Environmental Health Matters Initiative (EHMI) of the National Academies of Sciences, Engineering, and Medicine will host its first virtual workshop in a 3-part series on Indoor Air Management of Airborne Pathogens on August 18 from 11:30 am to 3:30 pm EDT. These workshops—follow ups to the 2020 workshop on the airborne transmission of SARS-CoV-2—will explore strategies needed for airborne disease control and risk reduction in enclosed places by drawing on accumulated community and institutional knowledge, on-the-ground observations of indoor environments management during the pandemic, and novel and promising scientific discoveries. For more information and to register, visit https://www.nationalacademies.org/event/07-21-2022/indoor-air-management-of-airborne-pathogens-lessons-practices-and-innovations.

 4. IMMUNE EVASION Immune escape, or immune evasion, is driving the COVID-19 pandemic’s extended life cycle. As the virus continues to infect humans, it will mutate and likely adapt to find its way around existing levels of vaccine-induced and natural immunity. The scientific community is not surprised that SARS-CoV-2 continues to evolve to evade our ever-changing immune systems, as many other viruses do the same. But because SARS-CoV-2 is a new virus to humans, attention is focused on emerging new variants and global anxiety is heightened, wondering what variant lies around the corner. 

Currently, there are many questions about whether the Omicron subvariants BA.2.75 or BA.4.6 will cause the next wave of infections. BA.2.75, which has been circulating widely in India for more than a month and has been detected in at least 20 other countries, does not currently appear likely to outcompete BA.5, the global leader of SARS-CoV-2 variants. BA.4.6, which is growing in prevalence in the US and Europe, appears to be just as transmissible as BA.2.75, but it remains unclear whether either subvariant will become predominant. Scientists continue to worry that either one of these Omicron subvariants, or an as-yet undetected variant, could gain global, regional, or local dominance. This cycle of new variant-driven waves, each with increased immune evasion, describes the global experience with COVID-19 to date, and many assume the pattern will continue into the future. This is what allowed BA.4 and BA.5 to spread widely despite widespread recent infections with the Omicron BA.1 and BA.2 subvariants. 

In addition to increased variant surveillance, more must be done to help further prepare for future increases in COVID-19 cases. The first priority is to address current infections by reducing transmission of circulating virus, limiting its chances to adapt and evade existing levels of immunity. However, limiting transmission is increasingly challenging, as many countries roll back mitigation measures and as funding for testing and vaccination programs dwindles. Many appear to be placing hope in the next generation of SARS-CoV-2 vaccines, which are expected to protect against a wider array of viral lineages. Several studies, including one conducted in non-human primates published this week in Science Translational Medicine, suggest that these vaccines may be a possibility, and they may be able to provide protection that extends to other coronaviruses, so-called pancoronavirus vaccines. While those vaccines remain a distant goal, manufacturers continue to work on current vaccine platforms that enable the fast production of variant-specific boosters. The CEO of Moderna recently compared the future of SARS-CoV-2 vaccines to the iPhone’s constant updates, with new generations developed as more data and technologies become available. 

5. NOVAVAX VACCINE Last month, the US FDA granted emergency use authorization (EUA) for a protein-based COVID-19 vaccine made by US-based manufacturer Novavax. Many public health advocates hoped that the vaccine’s authorization would lead to an increase in vaccinations among unvaccinated populations, having faith that the more traditional protein-based vaccine technology would ease concerns surrounding vaccination with vaccines using newer mRNA platforms. However, in the month since the EUA was issued, only about 7,400 doses have been administered in the US, with only 2,300 people receiving a 2-dose primary series using Novavax. According to the US CDC, 332,000 doses of the vaccine have been distributed nationwide. Originally, the vaccine was available at only 385 locations, although that number has grown to 986 sites. Notably, more than 53,000 locations have been used to provide other vaccinations throughout the pandemic. The limited uptake of the Novavax vaccine has received criticism given the large investment the company received from Operation Warp Speed. While it is too early to decide the fate of the vaccine in the US, Novavax recently reset its sales expectations, halving its forecast to US$2 billion to US$2.3 billion from US$4 billion to US$5 billion. 

AND LAST BUT NOT LEASED:

THE NORWEIGIAN REPORTS 1.5 INCHES OF RAIN. WHO SAYS PRAYER WON’T HELP. 

NEVER MIND. DON’T ANSWER THAT.

”THE DEVIL MADE ME DO IT:”

***********************************

GIVE US YOUR FEEDBACK.  CLICK ON “COMMENT” TO TELL US WHAT YOU THINK or use one of the alternative methods for providing feedback.

Click here to submit feedback.  Let us know what you think.

click here to CLOSE THIS PAGE

—————————————————————–

Click here to go to the iExposed.us youtube channel

Click here to go to the iExposed.us website

—————————————————————–

iExposed Us 

P.O. Box 721

Scottsville Texas

75688

CORONAVIRUS INFO PROVIDED BY DR. JIM HARRIS – 8/9/2022

COVID LEVELS IN OUR AREA ARE MODERATE AND HIGH 

SMITH AND CASS COUNTIES ARE HIGH.    USE CAUTION

FROM BECKERS:

Why US may be in for a severe flu season

”…Countries in the Southern Hemisphere are experiencing a severe flu season, which may be a harbinger of what’s to come for the U.S. this fall…

Health experts often look to the Southern Hemisphere’s flu season, which typically runs from April to September, as a predictor for the Northern Hemisphere’s upcoming flu season…Australia is facing its worst flu season in five years, with infections spiking for the first time since the COVID-19 pandemic began, according to data from Australia’s health department. Flu season also started earlier than usual in the country, giving the virus more time to circulate and infect the population….

Pharmacies and physician’s offices are expected to receive vaccine shipments in the coming weeks for the nation’s annual fall flu shot campaign. …”

Examination of SARS-CoV-2 In-Class Transmission at a Large Urban University With Public Health Mandates Using Epidemiological and Genomic Methodology

Findings  In this cohort study of 140 000 class meetings at a large US university, there were over 850 cases of SARS-CoV-2 infection identified through weekly surveillance testing of all students and faculty on campus during the fall 2021 semester. There were 9 instances of potential in-class transmission identified as identical lineages confirmed by SARS-CoV-2 genome sequencing, and none of these instances were confirmed to be in-class transmission.

Meaning  These results suggest that in-class transmission of SAR-CoV-2 in an urban university with masking and vaccine protocols in-place was negligible.

FROM JAMA:

1. Just the Plague: Reflections on State Control of Infectious Outbreaks

(J. Harris: A book review. The book is available at Amazon only in paperback at this time. I will wait for Kindle version.)

2. Animal Reservoirs—Where the Next SARS-CoV-2 Variant Could Arise

”…Understanding how the virus jumps between species—known to ecologists as a “spillover” event—is complicated but potentially critical in ending the COVID-19 pandemic….[including animals such as } big cats like tigers and lions but also domestic cats and dogs, gorillas, white-tailed deer, hamsters, farmed mink, otters, anteaters, manatees, hippopotamuses, and others… Interspecies transmission can produce new animal reservoirs where the virus can multiply or persist for prolonged periods, creating the potential for the pathogen to transmit back to human populations…”

(J. Harris: It is safer to sleep with a tomato than with a pet!)

3.Rate of SARS-CoV-2 Reinfection During an Omicron Wave in Iceland

”…Our results suggest that reinfection is more common than previously thought. Now the key question is whether infection with the Omicron variant will produce better protection against Omicron reinfection, compared with other variants…”

4. Association of Receiving a Fourth Dose of the BNT162b Vaccine With SARS-CoV-2 Infection Among Health Care Workers in Israel (Repeat I think)

”…In this multicenter cohort study of 29 611 health care workers in Israel, the breakthrough infection rate among those who received 4 doses was 6.9% compared with 19.8% in those who received 3 doses…”

Measuring work-related risk of COVID-19: comparison of COVID-19 incidence by occupation and industry – Wisconsin, September 2020-May 2021

”…During September 2020 – May 2021, the Wisconsin Department of Health Services collected occupation and industry data as part of routine COVID-19 case investigations. Adults aged 18-64 years with confirmed or probable COVID-19 in Wisconsin were assigned standardized occupation and industry codes….

Results

An estimated 11.6% of workers (347,013 of 2.98 million) in Wisconsin, ages 18-64 years, had COVID-19 from September 2020 to May 2021. The highest incidence by occupation (per 100 full-time equivalents) occurred among personal care and services workers (22.4), healthcare practitioners and support staff (20.7), and protective services workers (20.7). High risk sub-groups included nursing assistants and personal care aides (28.8), childcare workers (25.8), food and beverage service workers (25.3), personal appearance workers (24.4), and law enforcement workers (24.1). By industry, the incidence was highest in healthcare (18.6); the highest risk sub-sectors were nursing care facilities (30.5) and warehousing (28.5)…”

AND LASTLY:

My tolerance for idiots is extremely low these days. 

I used to have some immunity built up, but there must be a new strain out there?

***********************************

GIVE US YOUR FEEDBACK.  CLICK ON “COMMENT” TO TELL US WHAT YOU THINK or use one of the alternative methods for providing feedback.

Click here to submit feedback.  Let us know what you think.

click here to CLOSE THIS PAGE

—————————————————————–

Click here to go to the iExposed.us youtube channel

Click here to go to the iExposed.us website

—————————————————————–

iExposed Us 

P.O. Box 721

Scottsville Texas

75688

CORONAVIRUS INFO PROVIDED BY DR. JIM HARRIS – 8/4/202

COVID COUNTS ARE HIGH LOCALLY.

FROM THE NYT

1. By Jonathan Wolfe on 3 August:

”…Is the virus endemic?

Even though people across the world are trying to move on from Covid, it’s still here, all around us…Case in point: Half of all infections during the pandemic have taken place this year, … Given the current pace, it’s possible that more than 80 percent of all Covid cases will ultimately take place in 2022…

What do the coming months look like?

There are a lot of variables. [To] synthesize all of them, I would say that I think it’s likely that, for the foreseeable future, we’re living primarily with Omicron variants. That means the virus will find new ways to evade our immune response without totally eliminating the immune protections that we carried before….

In the fall, we will begin to see some limited rollout of new next-generation vaccines, but they won’t fundamentally change the trajectory of immune protection going forward. And we have very limited implementation of other social and political measures, such as mandating better air quality in schools and transportation systems and things along those lines….

”Where does that leave us? …That this is really an old person’s disease now. That was true at the beginning of the outbreak, but it’s becoming even more true now. It’s quite possible that we’ll see increasing relative vulnerability among the old, which is to say people who are in middle age are going to feel pretty safe living a totally normal life… But [older people]  may not ever. That’s because they have a much harder time building up immunity, which means they lose the benefits of the vaccines and previous exposure much more quicklyWe’re also seeing a significant death toll this year. We’ve more or less normalized it. We could have roughly equivalent numbers of especially elderly people dying as we did in the first years of the pandemic — and that’s tragic.”

FROM BECKERS:

Why we may be in ‘omicron land’ for a while

FROM HOPKINS SELECTIONS:Is the virus endemic?

Even though people across the world are trying to move on from Covid, it’s still here, all around us….attention to the US CDC’s guidance regarding isolation after COVID-19 diagnosis or a positive SARS-CoV-2 test. The CDC currently recommends isolation for a minimum of 5 days after the onset of symptoms or positive test. To end isolation, those who were symptomatic should wait until their fever has subsided for at least 24 hours and other symptoms are improving—and those leaving isolation should wear a mask in public through Day 10. Notably, the CDC indicates that individuals can test before they end their isolation, but the guidance emphasizes that testing is optional (ie, as opposed to recommended) for anyone who “wants to.” Those who elect to test and obtain a positive result should remain in isolation. The isolation and testing protocol implemented for President Biden went “above and beyond” the CDC recommendations, and CDC Director Dr. Rochelle Walensky indicated that the CDC must issue guidance that is feasible for most people to follow. Recent studies have demonstrated that many individuals continue to test positive for 6 days or longer, and most can shed the virus for 8 days or longer, which could enable them to infect others if they end isolation after 5 days. In light of this evidence, some experts have called on the CDC to revisit its guidance to slow transmission, particularly in light of the current Omicron surge.

2. ”… millions of people in the US have post-COVID-19 conditions, also known as long COVID. The US CDC estimates that nearly 1 in 5 individuals who have had COVID-19 continue to report long-term symptoms lasting 3 months or longer. Many of them have left their jobs because they have symptoms, such as fatigue or brain fog, that hinder their ability to perform daily or work tasks. Under federal guidance, people with long COVID can qualify for disability, meaning employers must offer accommodations to their workers. But many people with long COVID say negotiating accommodations or finding support from social assistance programs remains difficult. Some experts advocate for a better definition of the condition to facilitate diagnosis, more robust educational campaigns to warn people of the risk for long COVID, and more support for people with the condition. More than 100,000 US residents are diagnosed with COVID-19 everyday, some for a second or third time, and evidence suggests people who are infected more than once are at greater risk of long-term health consequences. It will be years before we fully understand the disease’s impacts on the public health, employment, and health coverage landscapes.

FROM THE ATLANTIC

This COVID Summer Is Nothing Like the Last One

”…We need multiple approaches to reduce transmission. It’s going bonkers right now, and this is not a sustainable way to coexist with this virus. I’m not saying that people need to have mask mandates forever, but when transmission rates are this high, it is a good idea to think about masking, to think about testing more often, paying attention to who is up-to-date on their vaccines and making sure that our approaches are complementing each other…

”It is true that hospitalization and death rates are down, but the more people you have infected, even a very small percentage can turn into an untenable number of hospitalizations and deaths. And every infection carries the risk of long COVID, or taking people away from school or work or their family. And the worrisome thing is, for the past few months, we’ve been at this bizarre plateau in terms of case counts not really coming back down and looking better…There’s not a lot of data to go off, so I’m going to be tentative here. I think we can expect them to be an improvement, but I can’t tell you if it’s going to be a 5 percent improvement or a 60 percent improvement. The other big asterisk on this is, what’s going to be around in September? Is it still going to be BA.5, is it going to be BA.6, or is it going to be another variant entirely?…We need multiple approaches to reduce transmission. It’s going bonkers right now, and this is not a sustainable way to coexist with this virus. I’m not saying that people need to have mask mandates forever, but when transmission rates are this high, it is a good idea to think about masking, to think about testing more often, paying attention to who is up-to-date on their vaccines and making sure that our approaches are complementing each other.

FROM EPIDEMOLOGIST:

How is monkeypox spread?

(J. Harris: This is concise and short. It will be all I have to say about Monkey Pox).

FROM THE LA TIMES:

Coronavirus Today: Experts are taking a softer stance on masking; it’s a different pandemic

(J. Harris: This is a good updated mask article. The majority of my readers are older folks with more than a few preexisting maladies — just like I have. I’m not going to goof off now and take careless chances at this late date. In addition, I don’t want to be dragging ass around in my last years with Long Covid. Masks and vaccinations and prudence have worked so far. Besides, I have to take care of both The Norwegian and Milton.)

FROM THE NEJM:

Grieving in a Pandemic

Viral and Symptom Rebound in Untreated COVID-19 Infection

”… Findings: In both the primary and secondary analyses, 12% of participants had viral rebound. Viral rebounders were older than non-rebounders (median 54 vs 47 years, P=0.04). Symptom rebound occurred in 27% of participants after initial symptom improvement and in 10% of participants after initial symptom resolution. The combination of high-level viral rebound to ≥5.0 log10 RNA copies/mL and symptom rebound after initial improvement was observed in 1-2% of participants. Interpretation: Viral RNA rebound or symptom relapse in the absence of antiviral treatment is common, but the combination of high-level viral and symptom rebound is rare.”

FROM JAMA

Association of Receiving a Fourth Dose of the BNT162b Vaccine With SARS-CoV-2 Infection Among Health Care Workers in Israel

Question: 

 Was there a benefit of vaccinating health care workers with a fourth dose of BNT162b2 vaccine during the Omicron variant outbreak of the COVID-19 pandemic?

Findings  In this multicenter cohort study of 29 611 health care workers in Israel, the breakthrough infection rate among those who received 4 doses was 6.9% compared with 19.8% in those who received 3 doses.

Meaning  These findings suggest that a fourth vaccine dose was effective in preventing breakthrough COVID-19 infections in health care workers, helping to maintain the function of the health care system during the [OMICRON] pandemic.

AND LASTLY, A SIGN SENT TO ME BY A CERTAIN NORWEGIAN:

A recent study has found women who carry a little extra weight live longer than men who mention it. 

***********************************

GIVE US YOUR FEEDBACK.  CLICK ON “COMMENT” TO TELL US WHAT YOU THINK or use one of the alternative methods for providing feedback.

Click here to submit feedback.  Let us know what you think.

click here to CLOSE THIS PAGE

—————————————————————–

Click here to go to the iExposed.us youtube channel

Click here to go to the iExposed.us website

—————————————————————–

iExposed Us 

P.O. Box 721

Scottsville Texas

75688

CORONAVIRUS INFO PROVIDED BY DR. JIM HARRIS – 7/25/2022

COVID State of Affairs: July 25 Katelyn Jetelina

(J. Harris: Great summary, readable. I am a paid subscriber.)

From THE NYT SATURDAY:

1. Combined nasal and throat testing swabs would detect more Omicron infections, two papers suggest.

”…coronavirus tests that analyze both nasal and throat swabs … pick up more Omicron infections than those that rely on just a nasal swab….

The first paper focuses on 14 people who enrolled in the study before or at the same time that their infections began, allowing the researchers to capture the earliest stage of infection….This group of participants provided a total of 260 nasal swabs, 260 throat swabs and 260 saliva samples over the course of their infections, allowing the scientists to make multiple comparisons between the amount of virus in different specimens and people at different times…

The researchers found significant differences in the viral load of different sample types from the same individuals….

In most participants, the virus was detectable in saliva or throat swabs before it was detectable in nasal swabs. “You can have very high, presumably infectious, viral loads in throat or saliva before nasal swabs,…”

2. New sub-variant ‘Centaurus’ discovered in Australia | Coronavirus | 9 News Australia

(J. Harris: It was hoped that the BA2.75 which started in India would not be an important varisn. Now called “Centaurus” in Australia, it isn’t as deadly as some variants, but much like BA .5 in the US, it is filling up some of the hospitals. Most of the world’s deaths from Covid are in folks over about 74.)

FROM LOCAL EPIDEMOLOGIST:

1. NORVAX: MIX AND MATCH DATA. PLUS SUMMARY OF THE NEW “OLD” VACCINE

1. 3.  Time-Release Microparticles Could Deliver “Self-Boosting” Vaccines (GEN) Most vaccines, from measles to COVID-19, require a series of multiple shots before the recipient is considered to be fully vaccinated. To make that easier to achieve, MIT researchers have developed microparticles that can be tuned to deliver their payload at different time points, and which could be used to create what the scientists describe as “self-boosting vaccines.” Using these particles, which resemble tiny coffee cups sealed with a lid, researchers could design vaccines that would need to be given just once, and would then “self-boost” at a specified point in the future. The particles can remain under the skin until the vaccine is released and then break down, just like resorbable sutures. The same strategy could also feasibly be used to deliver a range of other therapeutics, including cancer drugs, hormone therapy, and biologic drugs.

2. Polio: An unfortunate reminder of the decline in routine vaccinations

(J. Harris: We have the first acute polio case in the US in quite a while.)

From THE CDC:

 Correlation Between Clinical and Wastewater SARS-CoV-2 Genomic Surveillance, Oregon, USA (CDC EID) SARS-CoV-2 variant proportions in a population can be estimated through genomic sequencing of clinical specimens or wastewater samples. We demonstrate strong pairwise correlation between statewide variant estimates in Oregon, USA, derived from both methods (correlation coefficient 0.97). Our results provide crucial evidence of the effectiveness of community-level genomic surveillance.

FROM JAMA:

1. Effect of Text Message Reminders and Vaccine Reservations on Adherence to a Health System COVID-19 Vaccination Policy

”Question  Can a behavioral nudge delivered through text messages with a reserved date for vaccination over a 2-week period accelerate employee adherence with a health system COVID-19 vaccination policy?

Meaning  This randomized clinical trial found that a behavioral nudge delivered by text message with a reserved date for vaccination accelerated adherence to a health system COVID-19 vaccination policy; however, other approaches may be needed to change overall adherence rates by the time of the policy deadline.”

2. Association Between Vaccination and Acute Myocardial Infarction and Ischemic Stroke After COVID-19 Infection

This study found that full vaccination against COVID-19 was associated with a reduced risk of AMI [HEART ATTACK] and ischemic stroke after COVID-19. The findings support vaccination, especially for those with risk factors for cardiovascular diseases.

3. Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021

”…In this study of US blood donations, the combined seroprevalence from infection or vaccination reached 94.7% by December 2021. Despite this, record levels of infection and reinfections were reported as the Omicron variant became predominant in early 2022.2 The high infection rates are likely related to increased transmissibility and enhanced immune escape mutations of the Omicron variant, along with waning protection from previous vaccination and infection.3-5 During 2021, the infection-induced seroprevalence increased more in regions with low vaccination rates compared with those with high ones. The ability of SARS-CoV-2 variants to cause widespread transmission in the setting of high seroprevalence illustrates the value of COVID-19 vaccines, including recommended booster doses, to maximize protection.

FROM HOPINS SUGGESTIONS:

1. “…Published July 19 in Science, a study of spike protein function and neutralizing capability of 7 different SARS-CoV-2 vaccines against Omicron sublineages shows that a large number of the sublineage mutations lead to enhanced ACE2 binding and reduced plasma neutralizing activity. However, homologous or heterologous boosters markedly increased neutralizing antibody titers against BA.1, BA.2, BA.2.12.2, and BA.4/5 across all vaccines evaluated to provide sufficient protection against Omicron-induced severe disease. The vaccines evaluated included mRNA vaccines from Moderna and Pfizer-BioNTech, viral-vectored vaccines from J&J-Janssen, AstraZeneca-Oxford, and Sputnik V, as well as the Novavax and Sinopharm vaccines that use different platforms.

ADDITIONALLY FROM SCIENCE ARTICLE: ”…The recent evaluation of intranasal vaccine administration could also be important to not only prevent severe disease but also curtail viral infection and transmission through induction of mucosal immunity (75–78). For these reasons, it is important to monitor new variants, assess the effectiveness of currently available vaccines, and continue to test and implement new vaccination strategies that may provide stronger, longer lasting, or broader protection against SARS-CoV-2 and the entire sarbecovirus subgenus…”

2. US PANDEMIC PREPAREDNESS The administration of US President Joe Biden is reorganizing the US Department of Health and Human Services to elevate the Office of the Assistant Secretary for Preparedness and Response (ASPR) from a staff division into an independent operating division—similar to the US CDC, FDA, and NIH—responsible for leading the nation’s responses to future pandemics and health emergencies. Under the reorganization, ASPR will now be known as the Administration for Strategic Preparedness and Response, and efforts to stand up the new division will be phased in over the next 2 years. ASPR oversees the Strategic National Stockpile, the national Medical Reserve Corps, and contracts for and distribution of vaccines and certain medicines in health emergencies. Though many current and former HHS officials welcomed the move, other experts say that shifting some health emergency coordination responsibilities to ASPR could undercut response efficacy, create confusion and tension, and does not address ongoing challenges at CDC, which has much closer relationships with states. 

3. Prior Omicron Infection Protects Against BA.4 and BA.5 Variants (Nature) The Omicron BA.4 and BA.5 subvariants of SARS-CoV-2 have proven to be stealthier at evading people’s immune defences than all of their predecessors. But recent research shows that previous infection with an older variant (such as Alpha, Beta or Delta) offers some protection against reinfection with BA.4 or BA.5, and that a prior Omicron infection is substantially more effective. That was the conclusion of a study that evaluated all of Qatar’s COVID-19 cases since the wave of BA.4 and BA.5 infections began1. The work, which was posted on the medRxiv preprint server on 12 July and has not yet been peer reviewed, feeds into broader research on “how different immunities combine with each other”, says study co-author Laith Abu-Raddad, an infectious-disease epidemiologist at Weill Cornell Medicine-Qatar in Doha.

FROM SCIENTIFIC AMERICAN:

People with Long COVID May Still Have Spike Proteins in Their Blood

”...this spike protein found in the blood could be a “biomarker,” specifically for long COVID…”

”… researchers still haven’t pinned down what causes the condition or how to treat it…..Now researchers may have found a marker for the disabling condition: a piece of SARS-CoV-2, the virus that causes COVID, floating around in the blood of some long COVID sufferers well after their initial infection… detecting a fragment of SARS-CoV-2 in blood samples from long COVID sufferers up to a year after their original infection. The fragment is a spike protein, one of the protrusions around the outside of SARS-CoV-2 that give this coronavirus its namesake corona, or crownlike appearance. During an initial COVID infection, the spike protein typically breaks off into smaller pieces when it penetrates human cells, but the spike proteins observed in this study were still in one piece. The findings have not yet been peer-reviewed….“If you had an infection, and you cleared it, then normally, you would not see [the spike protein] because all the antibodies you produced would clear everything that enters the bloodstream,… Instead, …tissues such as those in the gut and brain could be a haven for SARS-CoV-2 within the body, preventing long COVID patients from fully clearing their infections and acting as a source of spike proteins. “Maybe the virus can just persist there. It evades the immune system somehow.”……[A] “The presence of circulating viral proteins may be helpful to identify which subset of long COVID patients might have the persistent viral etiology”—the version of long COVID caused by the ongoing presence of SARS-CoV-2 in the body—…The rest of the long haulers might suffer from other causes.” These other causes could include… [B] an overblown immune response that leads COVID patients’ body to develop immune proteins—“autoantibodies”—that attack its own cells in the same way they would attack an intruder such as a virus or bacterium. These autoantibodies have been found in people’s body during an initial COVID infection, as well as in the bodies of some long COVID patients…. [C]Another possibility is that a COVID infection makes people more susceptible to other viruses already present in the body, such as the Epstein-Barr virus. This pathogen lies dormant in most people but has been found reactivated in some long COVID patients…

FROM REUTERS:

Oral vaccine shows promise; hypertension ups COVID hospitalization risk

FROM BECKERS

BA.2.75 a ‘scariant,’ not the next variant to worry about, experts say

While there will likely be new COVID-19 variants to worry about in the future, omicron relative BA.2.75 is not the next big one to fret over, experts predict…

“BA.2.75 is a scariant. It’s not spreading anywhere besides a couple of provinces in India without BA.5 to compete with,” Eric Topol, MD, founder and director of the Scripps Research Translational Institute in San Diego, said in a July 19 tweet, citing a graph based on data from  global data-sharing virus platform GISAID that indicates the strain hasn’t spread much outside of several states in India. “There will be other new variants to be concerned about, but it doesn’t look like this is one of them.” 

As new variant spreads, a crucial drug to protect the most vulnerable goes vastly underused

(J. Harris: An IV drug against Covid for immunocompromised patients.)

***********************************

GIVE US YOUR FEEDBACK.  CLICK ON “COMMENT” TO TELL US WHAT YOU THINK or use one of the alternative methods for providing feedback.

Click here to submit feedback.  Let us know what you think.

click here to CLOSE THIS PAGE

—————————————————————–

Click here to go to the iExposed.us youtube channel

Click here to go to the iExposed.us website

—————————————————————–

iExposed Us 

P.O. Box 721

Scottsville Texas

75688

CORONAVIRUS INFO PROVIDED BY DR. JIM HARRIS – 7/21/2022

HOT OFF THE PRESS AND PERTINENT:

FROM THE NYT:

A guide to BA.5

”The Covid virus has a Darwinian quality. As variants emerge, they compete with one another to become dominant. The most contagious variants tend to win the competition because they can spread more quickly. It’s survival of the fittest...

That is why the virus has become more contagious over time. Today, the most contagious form of Covid yet — the BA.5 subvariant — is spreading around the globe. “It looks as if we are unable to control it,” Dr. Charles Chiu of the University of California, San Francisco, told The Times…In the U.S., cases have surged recently, as has the number of hospitalized patients with Covid (although some of them were admitted for other reasons and happened to test positive for the virus while in the hospital)…”

(J. Harris: And now President Biden has Covid.)

FROM HOPKINS COMPLETE REPORT:

COVID-19 Situation Repor [ AN UP TO DATE COVID SUMMARY]

Contributors: Clint Haines, MS; Noelle Huhn, MSPH; Amanda Kobokovich, MPH; Christina Potter, MSPH; Matthew Shearer, MPH; Marc Trotochaud, MSPH; and, Rachel A. Vahey, MHS.

”…CONCERN OVER BA.5 SUBVARIANT As the Omicron subvariant BA.5 drives increases in COVID-19 cases and hospitalizations in several regions and countries worldwide, health officials are, for the most part, holding back on sounding alarms. In the US, where the average number of cases and hospitalizations are at their highest levels since February, many state and local health authorities are characterizing the increase in cases as concerning but not disturbing, with many saying repeated warnings about COVID-19 surges are falling on pandemic-fatigued ears. However, US health officials are speaking out. White House COVID-19 Coordinator Dr. Ashish Jha has warned the BA.5 subvariant is the most immune evasive variant yet, urging US residents to stay up to date on their vaccines and expressing support for the reinstatement of mask mandates. Chief Medical Advisor to the US President Dr. Anthony Fauci called on eligible people to get vaccine boosters and said a decision about boosters for those under age 50 likely will soon be announced. In Europe, the WHO announced today that COVID-19 case numbers have tripled and hospitalizations have doubled across Europe over the past 6 weeks. WHO Europe Director Dr. Hans Kluge warned that people should not underestimate BA.5, calling on nations to bolster vaccine uptake and require mask wearing.

A dearth of data is complicating the true picture of how big BA.5-driven surges are, or will get, as publicly reported data has become less common due to the closing of testing sites and an increase in at-home test use. Some experts estimate that for every 1 reported case, there are 7-10 unreported cases. Additionally, BA.5 has several spike protein mutations that make it better at infecting human cells and evading immunity from vaccination or previous SARS-CoV-2 infection. These capabilities allowed the subvariant to gain predominance in the US in just over 2 months, and it is now causing 3 of every 4 new COVID-19 cases in the nation. BA.5 is so adept at skirting immune defenses that many people who were recently infected with a different Omicron variant are becoming reinfected. Some studies suggest that reinfections could cause lasting symptoms. And as the virus continues to circulate, there is a real risk of further mutations, meaning we likely will be living with some form of the virus for the foreseeable future.

VACCINE BOOSTERS The administration of US President Joe Biden is pressing the need for US residents aged 50 years and older and immunocompromised individuals to get their second COVID-19 vaccine booster as soon as possible due to the immune-evasive nature of the Omicron subvariant BA.5, as well as said a decision is expected soon about additional booster doses for all adults. According to US CDC estimates, BA.5 is now responsible for 78% of all new COVID-19 cases. Officials have stressed that booster doses provide additional protection against earlier Omicron subvariants and potentially later subvariants as well. However, current boosters have not yet been updated to more specifically target Omicron and its subvariants, leaving a dilemma for eligible individuals about whether to get a booster now or wait for updated versions. Additionally, some experts wonder and worry whether BA.5 will even be the predominant variant in the fall, potentially making new boosters less effective than expected.

Only 34% of the US population aged 5 years or older has received their first booster dose, COVID-19 pandemic response funding is dwindling, and public appetite for continued vaccinations is diminishing. All of these uncertainties create a perfect storm for risk communication difficulties for experts and officials alike, uncertain of the best course to recommend and how to inform the public about their choices. Some experts hope that next-generation vaccines, such as nasal vaccines—which may have a higher chance of preventing not just severe disease outcomes but also infection—or pan-coronavirus vaccines—which may work better against future variants as well as current variants—may help to boost vaccination rates. Additionally, the CDC is expected to make an announcement about its recommendations for the newly authorized Novavax vaccine later today. Some hope the protein-based vaccine also will help boost vaccination rates among unvaccinated individuals.

In related news, the British government on July 15 announced that individuals aged 50 or older, certain individuals in high-risk professions, and individuals over age 5 who are more likely to be at risk of severe disease outcomes will be eligible for a second booster dose in the fall. The announcement broadens eligibility beyond those who are aged 65 years and older.

YOUNG CHILD VACCINATIONS US medical experts and public health officials are expressing concern over low demand for COVID-19 vaccinations for the youngest children under age 5 and those ages 5-11. States were charged with ordering doses commensurate to expected demand, but some states’ orders only cover a small fraction of their child residents. For example, Mississippi has ordered enough vaccine doses to cover only 16% of its under-5 population with 1 dose. Florida did not preorder any doses for its under-5 population. Many parents there are struggling to find medical practitioners and health systems, which were able to independently order doses, that can provide the shots. The impacts are highest among families in underserved areas and those who rely on government-run health services. However, other experts caution that some states’ initial orders may not reflect future demands and childhood COVID-19 vaccination coverage. They say several factors may change over time, such as available vaccine storage, rampant misinformation, limited initial appointment slots, pushback from parents, reimbursement and logistical challenges, and some practitioners preferring to wait for full FDA approval prior to delivering vaccinations to younger populations.

Relatedly, Europe also may soon be administering vaccines to young children, as the European Medicines Agency (EMA) on July 18 began reviewing Pfizer-BioNTech’s vaccine for use in children aged 6 months to 4 years. Notably, increasing vaccination rates among young children at this point in the global response is paramount and could provide high impact. A recent study in JAMA Network Open found that antibody levels in previously infected individuals waned quickly over the first 200 days post-infection, with levels dropping most quickly in children under age 6.

WESTERN PACIFIC REGION A new wave of COVID-19 cases has hit the Western Pacific region, largely driven by the BA.4 and BA.5 Omicron subvariants. In Japan, cases are rising in every prefecture. The 7-day rolling average of new daily cases has surpassed February’s Omicron peak, and transmission does not seem to be slowing. The situation was further complicated by a 3-day weekend that saw high levels of activity at beaches and other tourist hotspots. The Japanese government is now trying to balance keeping the nation running with few restrictions while preventing hospitals from becoming overwhelmed. Cases also are rising in South Korea, where experts are predicting 200,000 daily cases by late-August, which would amount to half of the nation’s previous Omicron wave in March.

Hospitals in several Australian states are reaching capacity under the nation’s latest surge. Experts warn that while many emergency rooms are overwhelmed, most areas of the nation remain weeks away from their expected peak hospitalization rates. The situation is further complicated by a worse than average influenza season. According to data from the New York Times, New Zealand—a nation famous for early successes against COVID-19—now has the third highest daily confirmed rate of cases per 100,000 people of all nations, after Brunei and San Marino. Experts are concerned that the strain of new cases could lead to a collapse of the nation’s healthcare workforce. As a result, New Zealand officials are urging a renewed sense of urgency around COVID-19 precautions, including masking and testing.

In China, approximately 264 million people across 41 cities are under full or partial lockdown as part of the nation’s zero-COVID policy. Health experts are worried that the zero-COVID policy could become difficult to maintain given the increased transmissibility of the Omicron BA.4 and BA.5 subvariants. Some larger Chinese cities are rolling out new measures, such as mass testing and intense lockdowns, to try to curb the spread of the virus. There are growing concerns that increased COVID-19 prevention measures could further destabilize a struggling global economy.

ECONOMIC IMPACTS Fears of a global economic recession are on the rise. The global economic web was unsettled earlier this year when Russia invaded Ukraine, lowering the availability of energy, fertilizer, and food supplies. However, the largest disruptor of economic growth is the ongoing COVID-19 pandemic. The early phases of the pandemic disrupted the production of goods and the availability of services when governments implemented lockdowns to prevent transmission of the SARS-CoV-2 virus. However, the lockdowns prompted those stuck at home to begin ordering enormous volumes of goods over the internet. The combination of laborers stuck at home plus sky-high demand resulted in a global supply chain crisis. The supply chain crisis pushed prices for goods and services higher, and some industries have taken advantage of the global instability and their market dominance to secure record-breaking profits. Additional factors impacting inflation in the United States include an aggressive stimulus initiative and hesitancy by the Federal Reserve to increase interest rates.

The COVID-19 pandemic also is responsible for economic downturns in other nations with a large impact on the global market, including China. China has adopted an aggressive and highly controversial zero-COVID policy that has led to forced lockdowns in many of the country’s large cities. The lockdowns have prevented normal industrial operations that supply a large portion of the world’s manufactured goods. The disruption in production and shipping of goods has significantly slowed growth for the Chinese economy, which shrank by 2.6% during the latest quarter. This slowdown, which denotes a growth of only 0.4% from the end of June last year, represents the lowest growth rate since early 2020, when the nation completely shut down to fight the pandemic. The latest economic reports have cast doubt on whether China can reach its 5.5% growth target for the year set by the ruling Communist party.

However, a couple of recent studies hint that aggressive COVID-19 responses might limit economic damage in the long-term. One study, an assessment of business closure policies in New York City published by the International Monetary Fund, set out to determine the impact of closures in specific industries on the spread of COVID-19. According to the results, reopening businesses early allowed New York City to recover functionality as an economic hub but at the cost of a large wave of infections in 2020. The study also found that an alternative policy that extended lockdowns made future travel safer and was ultimately more cost-effective. Another study, examining the impact of long COVID on the workforce of the UK, estimated that 80,000 people have left the UK workforce due to long COVID as of March 2022. According to the authors, continued pandemic waves will lead to more people missing work, losing jobs, or permanently leaving the workforce due to long COVID. While many experts agree that a zero-COVID policy is unrealistic, it is becoming rapidly apparent that pretending like the pandemic is over may also lead to long-term and impactful health and economic consequences.

GLOBAL VACCINE ACCESS Last month, the 12th World Trade Organization (WTO) Ministerial Conference agreed to a version of a proposal for a global intellectual property waiver to allow countries to more easily use patented technologies to develop COVID-19 vaccines. Originally proposed only a few months into the pandemic by India and South Africa, and endorsed by more than 100 other nations, the approved deal on a Trade-Related Aspects of Intellectual Property (TRIPS) waiver is much narrower in scope than the original proposal and likely comes too late to make a significant impact on vaccine access. The deal does not include intellectual property waivers for diagnostics, treatments, or other COVID-19-related medical tools, and it excludes countries with “existing” production capacity. The power imbalances in both the COVID-19 pandemic and the WTO negotiations are apparent, from vaccine nationalism to sluggish negotiations. But over the past 2 years, low- and middle-income countries (LMICs) from South America to Africa have worked to solidify plans to cooperate on mRNA technologies in order to develop and produce their own versions of vaccines for SARS-CoV-2 and other diseases. This effort to collaboratively develop an mRNA vaccine technology transfer hub, which is supported by the WHO and the US NIH, must overcome significant challenges but provides hope for a new model to enable more LMICs to overcome future disease outbreaks more effectively, without having to rely on high-income countries or corporations…”’

”CRUISE SHIPS The US CDC announced on July 18 that its COVID-19 Program for Cruise Ships is no longer in effect. Although the agency will continue to publish guidance to help cruise ships provide safer and healthier environments for crews and passengers, the color-coded chart and spreadsheet that detailed the level of spread on ships is no longer available. According to a statement in the webpage’s FAQ section, the CDC is ending the program because it depended on each cruise line having the same testing and screening guidelines, which now all differ among companies. However, cruise ships will continue to report COVID-19 cases to the CDC, and passengers have the option of directly contacting their cruise line for information on outbreaks aboard their ship.

*****

FROM LOCAL EPIDEMOLOGIST:

NORVAX: MIX AND MATCH DATA. PLUS SUMMARY OF THE NEW “OLD” VACCINE

1. 3.  Time-Release Microparticles Could Deliver “Self-Boosting” Vaccines (GEN) Most vaccines, from measles to COVID-19, require a series of multiple shots before the recipient is considered to be fully vaccinated. To make that easier to achieve, MIT researchers have developed microparticles that can be tuned to deliver their payload at different time points, and which could be used to create what the scientists describe as “self-boosting vaccines.” Using these particles, which resemble tiny coffee cups sealed with a lid, researchers could design vaccines that would need to be given just once, and would then “self-boost” at a specified point in the future. The particles can remain under the skin until the vaccine is released and then break down, just like resorbable sutures. The same strategy could also feasibly be used to deliver a range of other therapeutics, including cancer drugs, hormone therapy, and biologic drugs.

2. Correlation Between Clinical and Wastewater SARS-CoV-2 Genomic Surveillance, Oregon, USA (CDC EID) SARS-CoV-2 variant proportions in a population can be estimated through genomic sequencing of clinical specimens or wastewater samples. We demonstrate strong pairwise correlation between statewide variant estimates in Oregon, USA, derived from both methods (correlation coefficient 0.97). Our results provide crucial evidence of the effectiveness of community-level genomic surveillance.

FROM JAMA:

Mix-and-Match COVID-19 Boosters After Inactivated Virus Vaccine

(J. Harris: It works)

FROM THE DMN:

Dallas County moved its internal COVID-19 risk level to “extreme caution” as case counts and hospitalization rise

”…BA.5 is most similar to BA.2, another omicron subvariant that picked up speed in Texas in March, although it has a few additional mutations on its spike protein,…A BA.5 infection seems to come with the same symptoms as the original omicron strain, including headache, a sore throat, a runny nose, fever and fatigue.

While the loss of taste and smell were tell-tale signs of COVID-19 infection with the alpha and delta variants, they’re much less likely with infections from omicron and its subvariants. A May study from researchers at Virginia Commonwealth University found that chances of smell and taste loss were just 17% for omicron, compared to 50% for the alpha variant….There’s also the risk of long COVID, which can lead to sometimes debilitating symptoms like fatigue and neurological issues for months after an initial infection. It’s estimated that anywhere from 10% to 30% of COVID-19 patients might experience long COVID, according to the American Medical Association…CDC and other federal health officials have repeatedly said that people should get boosted now… go ahead and get it and not wait until the new versions of the vaccine are released, especially if you’ve got anything of significance that you’re planning in the next two or three months like a trip or a wedding,” he said. “You don’t want COVID to mess those plans up.”

Recommendations for avoiding COVID-19 in the red risk level

Wear a mask indoors when in public.

Stay up to date with COVID-19 vaccines, including booster doses.

Get tested if you notice any COVID-19 symptoms.

Increase ventilation when indoors by turning on fans or opening windows to increase air circulation.)

(J. Harris: I think avoid crowds and gatherings is very important in our area. Marshall  counts are down only because nobody is counting. The majority of the clinics and doctors and hospitals are not in Marshall. Fortunately, we have plenty of funeral homes.)

FROM REUTERS:

Australians urged to work from home as winter Omicron wave swamps hospitals

LASTLY:

And I just couldn’t resist this current ”photo”:

***********************************

GIVE US YOUR FEEDBACK.  CLICK ON “COMMENT” TO TELL US WHAT YOU THINK or use one of the alternative methods for providing feedback.

Click here to submit feedback.  Let us know what you think.

click here to CLOSE THIS PAGE

—————————————————————–

Click here to go to the iExposed.us youtube channel

Click here to go to the iExposed.us website

—————————————————————–

iExposed Us 

P.O. Box 721

Scottsville Texas

75688